Celltrion Pharm, Inc. (068760.KQ)
KRW 61300.0
(-3.01%)
KRW 61300.0
(-3.01%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 54.22 Billion KRW | 0.29% |
| 2022 | 54.1 Billion KRW | -13.36% |
| 2021 | 64.25 Billion KRW | 72.94% |
| 2020 | 37.1 Billion KRW | 33.64% |
| 2019 | 27.76 Billion KRW | 74.84% |
| 2018 | 12.41 Billion KRW | -23.83% |
| 2017 | 20.84 Billion KRW | 791.21% |
| 2016 | -2.92 Billion KRW | -138.55% |
| 2015 | -9.09 Billion KRW | 82319.82% |
| 2014 | 9.49 Billion KRW | 9.13% |
| 2013 | 8.69 Billion KRW | 95.2% |
| 2012 | 5.43 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 8.82 Billion KRW | 9.9% |
| 2024 Q2 | 14.41 Billion KRW | 60.06% |
| 2023 Q3 | 11.8 Billion KRW | -39.86% |
| 2023 Q4 | 10.38 Billion KRW | -12.1% |
| 2023 FY | - KRW | 0.29% |
| 2023 Q1 | 13.92 Billion KRW | 31.6% |
| 2023 Q2 | 19.63 Billion KRW | 41.01% |
| 2022 FY | - KRW | -13.36% |
| 2022 Q4 | 10.58 Billion KRW | -40.79% |
| 2022 Q1 | 11.96 Billion KRW | -7.34% |
| 2022 Q3 | 17.87 Billion KRW | 17.75% |
| 2022 Q2 | 15.17 Billion KRW | 26.88% |
| 2021 Q3 | 17.19 Billion KRW | -16.68% |
| 2021 Q4 | 12.9 Billion KRW | -24.91% |
| 2021 Q2 | 20.63 Billion KRW | 53.68% |
| 2021 Q1 | 13.42 Billion KRW | 119198.08% |
| 2021 FY | - KRW | 72.94% |
| 2020 Q3 | 9.02 Million KRW | -0.71% |
| 2020 FY | - KRW | 33.64% |
| 2020 Q4 | 11.25 Million KRW | 24.7% |
| 2020 Q2 | 9.08 Million KRW | 17.57% |
| 2020 Q1 | 7.73 Million KRW | -12.58% |
| 2019 FY | - KRW | 74.84% |
| 2019 Q3 | 7.31 Million KRW | 1.53% |
| 2019 Q1 | 4.4 Million KRW | -41.6% |
| 2019 Q4 | 8.84 Million KRW | 20.96% |
| 2019 Q2 | 7.2 Million KRW | 63.49% |
| 2018 Q2 | 2.67 Million KRW | -40.14% |
| 2018 FY | - KRW | -23.83% |
| 2018 Q1 | 4.46 Million KRW | -1.91% |
| 2018 Q4 | 7.54 Million KRW | 531.84% |
| 2018 Q3 | 1.19 Million KRW | -55.36% |
| 2017 Q1 | 3.16 Million KRW | 122.08% |
| 2017 Q2 | 8.71 Million KRW | 175.19% |
| 2017 FY | - KRW | 791.21% |
| 2017 Q4 | 4.55 Million KRW | 3.12% |
| 2017 Q3 | 4.41 Million KRW | -49.29% |
| 2016 Q3 | 4.27 Million KRW | -2.82% |
| 2016 FY | - KRW | -138.55% |
| 2016 Q1 | 2.64 Million KRW | 117.42% |
| 2016 Q2 | 4.4 Million KRW | 66.6% |
| 2016 Q4 | -14.33 Million KRW | -435.19% |
| 2015 Q3 | 1.92 Million KRW | -7.0% |
| 2015 Q2 | 2.07 Million KRW | 0.02% |
| 2015 Q1 | 2.07 Million KRW | -34.39% |
| 2015 FY | - KRW | 82319.82% |
| 2015 Q4 | -15.16 Million KRW | -887.27% |
| 2014 Q3 | 2.78 Million KRW | -2.59% |
| 2014 FY | - KRW | 9.13% |
| 2014 Q4 | 3.15 Million KRW | 13.36% |
| 2014 Q2 | 2.85 Million KRW | 169.47% |
| 2014 Q1 | 1.06 Million KRW | -39.67% |
| 2013 Q3 | 2.43 Million KRW | 8.56% |
| 2013 FY | - KRW | 95.2% |
| 2013 Q1 | 2.26 Million KRW | 82.28% |
| 2013 Q4 | 1.75 Million KRW | -27.74% |
| 2013 Q2 | 2.24 Million KRW | -1.02% |
| 2012 Q4 | 1.24 Million KRW | 0.0% |
| 2012 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 581.09 Million KRW | -9231.425% |
| CMG Pharmaceutical Co., Ltd. | 5.59 Billion KRW | -869.237% |
| Huons Global Co., Ltd. | 151.92 Billion KRW | 64.31% |
| DongKook Pharmaceutical Co., Ltd. | 88.68 Billion KRW | 38.858% |
| Enzychem Lifesciences Corporation | -5.77 Billion KRW | 1039.155% |
| Humedix Co., Ltd. | 54.87 Billion KRW | 1.185% |
| Boditech Med Inc. | 36.48 Billion KRW | -48.606% |
| EuBiologics Co., Ltd. | -4.39 Billion KRW | 1334.659% |
| FutureChem Co.,Ltd | -591.25 Million KRW | 9270.982% |
| Huons Co., Ltd. | 74.23 Billion KRW | 26.954% |
| BNC Korea Co., Ltd. | 14.17 Billion KRW | -282.627% |
| AptaBio Therapeutics Inc. | -13 Billion KRW | 516.961% |